🇺🇸 FDA
Pipeline program

ALX1-11 (drug)

CL1-11-002

Phase 3 small_molecule completed

Quick answer

ALX1-11 (drug) for Osteoporosis is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Osteoporosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials